{"id":23790,"date":"2022-12-06T17:50:00","date_gmt":"2022-12-06T09:50:00","guid":{"rendered":"https:\/\/flcube.com\/?p=23790"},"modified":"2025-01-29T18:02:32","modified_gmt":"2025-01-29T10:02:32","slug":"novo-nordisk-and-atlatl-announce-winners-of-entrestar-program-for-pharma-start-ups","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23790","title":{"rendered":"Novo Nordisk and ATLATL Announce Winners of EntreStar Program for Pharma Start-Ups"},"content":{"rendered":"\n<p>Novo Nordisk Research Centre China (NNRCC) and the innovation incubator ATLATL jointly announced the winners of the EntreStar program, a competition for China-based pharma start-ups. The winners were Hangzhou DNano MetaBio Technology and Modit Therapeutics both of which stand to receive RMB 500,000 (USD 71,550) and gain free access to ATLATL\u2019s incubator sites across the country, as well as mentoring from relevant experts at Novo Nordisk (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>).<\/p>\n\n\n\n<p><strong>Winning Start-Ups and Their Innovations<\/strong><br>Both firms are start-ups founded in 2022. Hangzhou DNano MetaBio Technology is described as focusing on the design of nucleic acid nanocarriers with customized functions \u201cand great potential in clinical translation,\u201d with internal capabilities in nucleic acid structure design, allowing accurate regulation of the organ-targeting ability and the on-demand drug release performance of nanocarriers.<\/p>\n\n\n\n<p>Modit Medicine Inc., meanwhile, focuses on RNA editing and therapeutics. The company owns cutting-edge and proprietary RNA modification and editing methodologies and is devoted to the development of novel platform technologies. Instead of manipulating DNA sequences, Modit\u2019s technology is capable of correcting genetic errors at the RNA level, with the expectation that safe and highly effective therapeutics for rare diseases, oncology, and other fields will emerge.<\/p>\n\n\n\n<p><strong>Background on NNRCC and ATLATL<\/strong><br>Novo Nordisk set up the NNRC in 1997, the first research center to be established by an MNC in China, with a focus on protein and peptide therapeutic research. ATLATL, meanwhile, operates innovation incubators at pharma hub sites across China, including Shanghai, Beijing, and Suzhou. The firm states it also covers R&amp;D assembly services for biotech companies, with specialist focus on gene and cell therapy, drug discovery, single-cell research, GMP implementation, animal disease models, as well as preclinical pharmacology and toxicology studies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk Research Centre China (NNRCC) and the innovation incubator ATLATL jointly announced the winners&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[30,3378,3380,860,64],"class_list":["post-23790","post","type-post","status-publish","format-standard","hentry","category-company","tag-biotech","tag-dnano-metabio-technology","tag-modit-therapeutics","tag-nyse-nvo","tag-rnai-aso"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk and ATLATL Announce Winners of EntreStar Program for Pharma Start-Ups - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk Research Centre China (NNRCC) and the innovation incubator ATLATL jointly announced the winners of the EntreStar program, a competition for China-based pharma start-ups. The winners were Hangzhou DNano MetaBio Technology and Modit Therapeutics both of which stand to receive RMB 500,000 (USD 71,550) and gain free access to ATLATL\u2019s incubator sites across the country, as well as mentoring from relevant experts at Novo Nordisk (NYSE: NVO).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23790\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk and ATLATL Announce Winners of EntreStar Program for Pharma Start-Ups\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23790\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-06T09:50:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-29T10:02:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23790#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23790\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk and ATLATL Announce Winners of EntreStar Program for Pharma Start-Ups\",\"datePublished\":\"2022-12-06T09:50:00+00:00\",\"dateModified\":\"2025-01-29T10:02:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23790\"},\"wordCount\":296,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"DNano MetaBio Technology\",\"Modit Therapeutics\",\"NYSE: NVO\",\"RNAi \\\/ ASO\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23790#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23790\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23790\",\"name\":\"Novo Nordisk and ATLATL Announce Winners of EntreStar Program for Pharma Start-Ups - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-12-06T09:50:00+00:00\",\"dateModified\":\"2025-01-29T10:02:32+00:00\",\"description\":\"Novo Nordisk Research Centre China (NNRCC) and the innovation incubator ATLATL jointly announced the winners of the EntreStar program, a competition for China-based pharma start-ups. The winners were Hangzhou DNano MetaBio Technology and Modit Therapeutics both of which stand to receive RMB 500,000 (USD 71,550) and gain free access to ATLATL\u2019s incubator sites across the country, as well as mentoring from relevant experts at Novo Nordisk (NYSE: NVO).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23790#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23790\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23790#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk and ATLATL Announce Winners of EntreStar Program for Pharma Start-Ups\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk and ATLATL Announce Winners of EntreStar Program for Pharma Start-Ups - Insight, China&#039;s Pharmaceutical Industry","description":"Novo Nordisk Research Centre China (NNRCC) and the innovation incubator ATLATL jointly announced the winners of the EntreStar program, a competition for China-based pharma start-ups. The winners were Hangzhou DNano MetaBio Technology and Modit Therapeutics both of which stand to receive RMB 500,000 (USD 71,550) and gain free access to ATLATL\u2019s incubator sites across the country, as well as mentoring from relevant experts at Novo Nordisk (NYSE: NVO).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23790","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk and ATLATL Announce Winners of EntreStar Program for Pharma Start-Ups","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=23790","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-12-06T09:50:00+00:00","article_modified_time":"2025-01-29T10:02:32+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23790#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23790"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk and ATLATL Announce Winners of EntreStar Program for Pharma Start-Ups","datePublished":"2022-12-06T09:50:00+00:00","dateModified":"2025-01-29T10:02:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23790"},"wordCount":296,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","DNano MetaBio Technology","Modit Therapeutics","NYSE: NVO","RNAi \/ ASO"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23790#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23790","url":"https:\/\/flcube.com\/?p=23790","name":"Novo Nordisk and ATLATL Announce Winners of EntreStar Program for Pharma Start-Ups - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-12-06T09:50:00+00:00","dateModified":"2025-01-29T10:02:32+00:00","description":"Novo Nordisk Research Centre China (NNRCC) and the innovation incubator ATLATL jointly announced the winners of the EntreStar program, a competition for China-based pharma start-ups. The winners were Hangzhou DNano MetaBio Technology and Modit Therapeutics both of which stand to receive RMB 500,000 (USD 71,550) and gain free access to ATLATL\u2019s incubator sites across the country, as well as mentoring from relevant experts at Novo Nordisk (NYSE: NVO).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23790#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23790"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23790#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk and ATLATL Announce Winners of EntreStar Program for Pharma Start-Ups"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23790"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23790\/revisions"}],"predecessor-version":[{"id":23793,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23790\/revisions\/23793"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23790"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23790"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}